Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gh Research Plc (NQ: GHRS )

9.070 -0.550 (-5.72%)
Streaming Delayed Price Updated: 10:21 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,121
Open 9.570
Bid (Size) 8.990 (1)
Ask (Size) 9.150 (1)
Prev. Close 9.620
Today's Range 9.050 - 9.945
52wk Range 5.050 - 14.99
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
3 Fast-Growing Stocks Analysts See Doubling in Price
Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches. 
Via MarketBeat

Performance

YTD
+69.53%
+69.53%
1 Month
+9.28%
+9.28%
3 Month
-18.36%
-18.36%
6 Month
-31.96%
-31.96%
1 Year
+31.26%
+31.26%

More News

Read More
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
Via Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
Via Talk Markets
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
Via Talk Markets
Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials
Via Benzinga
GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
From GH Research PLC
Via GlobeNewswire
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
Via Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
Via Talk Markets
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
Via Talk Markets
3 Psychedelic Stocks to Ride to the Moon and Beyond
Via InvestorPlace
Exposures Product Safety
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns
Via InvestorPlace
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Via Talk Markets
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
Via Talk Markets
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Via Talk Markets
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
Via Talk Markets
GHRS Stock Earnings: GH Research Beats EPS for Q1 2024
Via InvestorPlace
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
Via Talk Markets
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD
Via Talk Markets
March Recap: Largest Psychedelic Drug Stocks Up Another 5%
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.